A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course.

Background: The diagnostic use of biomarkers in body fluids of multiple sclerosis (MS) patients allows the monitoring of different pathophysiological aspects of the disease. We previously reported elevated cerebrospinal fluid (CSF) and serum levels of glial fibrillary acidic protein (GFAP) but not n... View More